Table 2 Obstructive Sleep Apnea severity parameters (some reported from previous study²³), main sleep characteristics, and heart rate variability (HRV) at baseline, on placebo, and on active drugs combination (n = 16); HRV was assessed from EKG of nocturnal PSG during N2 sleep at baseline, on placebo, and on active drugs combination.

	Baseline	Placebo	Reb-Oxy	p-value
Full night PSG
AHI total, events/h	48.7 [34.8–56.6]	38.7 [29.0–47.8]	18.0 [12.5–21.4]	< 0.01
Hypoxic burden, %min/h	90.8 [69.5–154]	75.5 [68.1–168.0]	39.7 [25.4–55.3]	< 0.01
ODI 3%, events/h	42.7 [32.3–53.0]	36.8 [23.8–43.2]	31.4 [19.1–37.7]	0.03
Total sleep time, min	329.5 [301.0–368.8]	323.5 [274.4–351.4]	321.8 [283.0–362.9]	0.50
PLM index, events/h	0.0 [0.0–2.8]	0.0 [0.0–2.8]	0.5 [0.0–2.8]	0.81
HR, bpm	65 [59.5–69]	65.6 [58.8–69.55]	69.35 [63.8–76.75]	0.02
HRV in N2 phase
RMSSD, ms²	40.4 [17.5–51.6]	24.7 [17.6–43.1]	32.4 [25.4–51.6]	0.38
pNN50	0.18 [0.01–0.32]	0.02 [0.001–0.18]	0.10 [0.03–0.35]	0.40
HF, ms²	300.0 [90.7–748.4]	189.7 [85.6–527.2]	328.8 [181.5–887.9]	0.53
LF, ms²	370.2 [136.9–1021.4]	222.8 [159.1–1099.7]	371.47 [227.8–614.94]	0.38
LF/HF	2.4 [0.9–3.9]	1.3 [0.9–2.4]	1.1 [0.6–1.7]	0.46
VLF, ms²	680.6 [341.1–2879.1]	504.4 [232.3–2095.3]	659.4 [434.4–885.6]	0.25

reb–oxy = reboxetine plus oxybutynin; AHI = apnea–hypopnea index; ODI = oxygen desaturation index; PLM = periodic legs movements; HR = heart rate; SD = standard deviation; RMSSD = Root Mean Square of the Successive Differences; pNN50 = the proportion of number of pairs of successive NN (R-R) intervals that differ by more than 50 ms; HF = high frequency; LF = low frequency; VLF = very low frequency.
Data are presented as median [interquartile] % changes are expressed as the median of percentage change. P values compare placebo versus reb-oxy.
P-values are calculated by comparing the percentage changes from baseline observed in the placebo versus reb-oxy.

Search